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PIntramyocardial injection of tannic acid attenuates postinfarction
remodeling: A novel approach to stabilize the breaking extracellular
matrix
Hao Zhang, MD, PhD,a,b Shen-jun Zhu, MD,a De Wang, MD, PhD,a Ying-jie Wei, PhD,a and Sheng-Shou Hu, MDa,b
Objective: Myocardial infarction is associated with early matrix metalloproteinase activation and extracellular
matrix degradation. We tested the hypothesis that stabilizing the original extracellular matrix of the infarcted
left ventricle with local injection of tannic acid would preserve cardiac structure and function.
Methods: In vitro cytotoxicity of tannic acid was performed first; myocardial infarction model was induced by
ligation of the left anterior descending branch in rats. Tannic acid was intramyocardially injected into infarcted
site 24 hours after myocardial infarction (n¼ 30), and saline solution was injected in the same way as in the con-
trol (n ¼ 30). The matrix metalloproteinase activity from tannic acid/saline solution–treated tissues was assayed
by gelatin zymography 24 hours and 1 week after the treatment. The collagen content in the infarcted area was
evaluated by hydroxyproline colorimetry assay 1 and 4 weeks after the treatment. Left ventricular structure and
function were also evaluated with echocardiography, hemodynamics, and histologic examination.
Results: Tannic acid at a concentration of 0.05% had minimal cytotoxic effects on cultured cardiomyocytes and
thus was subsequently chosen as the optimal concentration for injection. Compared with the saline solution in-
jection group, tannic acid treatment inhibited the matrix metalloproteinase-2/-9 activity and increased the collagen
content at the early post–myocardial infarction stage (48.6  7.2 vs 37.3  6 mg/mg dry weight). Tannic acid
treatment also significantly reduced infarct expansion (infarct expansion index: 1.04  0.15 vs 1.42  0.21)
and left ventricular dilatation at 4 weeks after infarction. Although tannic acid treatment improved fractional
shortening (26%  2.4% vs 23.3%  3.2%), it failed to alter blood pressure (systolic blood pressure: 93.8
 8.2 vs 90.6  8.5 mm Hg) and rate of pressure rise.
Conclusions: Local delivery of tannic acid prevents collagen matrix degradation via cross-linking fibrous colla-
gen and inhibiting matrix metalloproteinase activity but does not improve the intrinsic contractile function of
myocardium. This treatment may be helpful to attenuate the adverse topographic remodeling after acute myocar-
dial infarction.Supplemental material is available online.
Cardiac extracellular matrix (ECM) mainly consists of a 3-
dimensional collagen architecture, which is critical to retain
tissue integrity and facilitate the conversion of single cardi-
ocyte contraction into global pump function. In the setting of
myocardial infarction (MI), the activation of matrix metallo-
proteinase (MMP) and enzymatic degradation of ECM play
critical roles in scar expansion, ventricular dilation, ventric-
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farct expansion initiates adverse remodeling, leads to left
ventricular dilation, and portends a poor long-term outcome.
To retard the early adverse post-MI remodeling, various ef-
forts have been attempted to preserve or restore the ECM
after MI (discussed in details in the excellent review by
Spinale1).
Tannic acid (TA), a natural extract of plant polyphenol, has
been shown to physically cross-link collagen and elastin and
hence improve their resistance to the enzymatic degrada-
tion.2,3 Collagen is a protein with a fiber structure and, by
introducing multiple hydrogen bonds, can be physically
cross-linked by TA and resist to resolution and enzymatic
degradation. Furthermore, in previous tumor studies, it has
been suggested that TA can inhibit MMP activities and thus
suppress the invasiveness and metastasis of cancer cells.4
Considering the above facts, we hypothesized that intra-
myocardial injection of TA at the early stage of MI would
stabilize collagen matrix and attenuate early left ventricular
(LV) remodeling via direct collagen cross-linking and MMP
activities suppression. Therefore, in this study we wanted to
address: (1) the biosafety of TA for in vivo use; (2) whether
local injection of TA can maintain the integrity of ECM ar-
chitecture and thus thicken the scar tissue and limit infarctgery c January 2009




DMEM ¼ Dulbecco’s modified Eagle medium
ECM ¼ extracellular matrix
EDD ¼ end-diastolic dimensions
ESD ¼ end-systolic dimensions
FS ¼ fractional shortening
LV ¼ left ventricular
MI ¼ myocardial infarction
MMP ¼ matrix metalloproteinase
MTT ¼ 3-[4,5-dimethylthiazol-2-yl]-2,
5-diphenyl tetrazolium bromide
OCT ¼ optimum cutting temperature
PBS ¼ phosphate-buffered saline solution
SD ¼ Sprague-Dawley
TA ¼ tannic acid
TIMP-2 ¼ tissue inhibitor of metalloproteinase-2
expansion; (3) whether TA injection can improve damaged
heart function; and (4) the underlying mechanisms behind
TA treatment.
METHODS
In vitro Cytotoxicity Assessment
Cardiomyocytes were obtained by enzymatic digestion of the left ventri-
cles from Sprague-Dawley (SD) rats, as previously described.5 The cells
were seeded in 96-well plates (5000 cells/well) in Dulbecco’s modified
Eagle medium (DMEM) with 10% fetal bovine serum, in a humidified in-
cubator at 37C with 5% CO2. When the cells were 95% confluent, they
were exposed to increasing concentrations of TA (0.025%, 0.05%,
0.10%, 0.15%, and 0.20% TA in phosphate-buffered saline solution
[PBS]), and cell viability was assessed by the MTT (3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyl tetrazolium bromide) assay as previously described.6
Briefly, solution of MTT (Sigma-Aldrich, St Louis, Mo) was prepared in
DMEM and added to each well at a final concentration of 0.5 mg/mL after
removal of the culture medium, after which the cells were incubated at 37C
for 4 hours. The supernatants were removed from the wells, and 100 mL di-
methyl sulfoxide was added to each well to dissolve the blue formazan prod-
uct. Quantitative colorimetric assay at 570 nm was measured on a 96-well
scanning spectrophotometer. Cardiomyocytes were also incubated with
PBS and 70% ethanol as negative and positive controls, respectively.
Animal Experiments
Acute myocardial infarction was induced by ligation of the proximal left
coronary artery in 8-week-old male SD rats (280 to 300 g) as previously de-
scribed.7 All animal experimental procedures were approved by the Ethic
Committee for Animal Study in Fuwai Hospital and conformed to the guide-
lines in the ‘‘Regulation to the Care and Use of Experimental Animal’’
(1996) of the Beijing Council on Animal Care. In brief, the animals were
intubated with an 18-gauge intravenous catheter and ventilated at a rate of
65 cycles/min with a tidal volume of 2.5 mL under room air supplemented
with oxygen (0.2 L/min) and 1.0% to 2.0% isoflurane using a Harvard ven-
tilator (model 683, Harvard Apparatus, Holliston, Mass). After the chest
was cleaned and shaved, through a left lateral thoracotomy, the proximal
left coronary artery was ligated with a 6–0 polypropylene suture. After myo-The Journal of Thoracic and Ccardial ischemia was confirmed by regional myocardial color change, the in-
cision was closed in layers with 3–0 silk running sutures. Twenty-four hours
later, the rats were reanesthetized and underwent echocardiography exami-
nation. Sixty of the survival rats with LV fractional shortening (FS) at
a range of 20% to 30% were randomized into 2 groups: TA group (n ¼
30) and control group (n¼ 30). Then the chest was reopened via the old in-
cision, and the grayish infarcted myocardiumwas exposed. Then, 100 mL of
0.05% TA or saline solution was injected into 2 sites located in the infarcted
and borderline area with a 29-gauge insulin syringe (50 mL per site). After
the second surgery, the rats were allowed to recover and were housed in
a clean laboratory room with a temperature-controlled environment under
a 12-hour light–dark cycle and fed with free access to food and water.
The entire animal experimental protocol was described in Figure 1.
Assay of MMP/Tissue Inhibitor of Metalloproteinase
Expression and Activities
To assess the inhibitory effect of TA on post-MI MMP activity, 4 rats
from each group were killed either 24 hours or 1 week after TA/saline injec-
tion. The infarcted LV tissue (injection site) was separated and homoge-
nized. The activity of myocardial collagenases (MMP-2 and -9) was
analyzed by gelatin zymography as described elsewhere.8 In brief, 8% sub-
strate gel was prepared with gelatin (final concentration of 1.0 mg/mL). A
total of 20 mg protein was loaded per lane without reduction. After electro-
phoresis, the gel was washed twice for 15 minutes each with 2.5% Triton X-
100. Then the gel was incubated overnight at 37C in substrate buffer (0.5
mol/L Tris-HCl, pH 6.8, 0.5% CaCl2, 0.2 mol/L NaCl, 0.2% Brij-35 and
0.02% NAN3). After incubation, the gel was stained for 1 hour in 0.25%
Coomassie brilliant blue R-250 in acetic acid:methanol:water (1:4.5:4.5
by volume), destained in 10% acetic acid, and scanned for lytic activity
and photographed. Gelatinolytic activity of MMP-2 and -9 was detected
as transparent bands on the Coomassie brilliant blue–stained gel. To inves-
tigate whether the TA can directly inhibit the gelatinolytic activity, TA was
added into the incubation buffer with a final concentration of 50 mg/mL in
a separate zymography assay with the samples from the control group.
Furthermore, to figure out whether TA can influent the expression of
MMP, another 4 rats from each group were killed at 24 hours, and Western
blotting was performed to determine the protein level of MMP-2, -9, and
one of their endogenous inhibitors, tissue inhibitor of metalloproteinase-2
(TIMP-2), using the corresponding primary antibodies (anti-MMP-2,
from Santa Cruz Biotechnology [Santa Cruz, Calif]; anti-MMP-9 and
anti-TIMP-2, from Chemicon International, Temecula, Calif).
FIGURE 1. Scheme of in vivo experimental protocol. MI, Myocardial in-
farction; TA, tannic acid; MMP, matrix metalloproteinase.ardiovascular Surgery c Volume 137, Number 1 217
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PCollagen Content Evaluation by Hydroxyproline
Assay
One and 4 weeks after TA/saline solution injection, myocardial collagen
content in the infarcted region was measured by hydroxyproline assay using
a modified Stegemann protocol.9 Briefly, samples of infarct myocardium
from 5 rats at different times from each group were carefully separated
and lyophilized to a constant weight. Each sample was homogenized in
0.1 mol/L NaCl and 5 mmol/L NaHCO3, washed with the same solution
5 times, and hydrolyzed in 1 mL of 6 mol/L HCl for 24 hours at 100C, fol-
lowed by neutralization with 6 mol/L NaOH. Isopropanol, chloramine-T re-
agent, and Ehrlich’s reagent solution were added, and the samples were
mixed and incubated at 60C for 30 minutes. The absorbency of the samples
was read at 560 nm, and the hydroxyproline concentration was assessed us-
ing a curve obtained from hydroxyproline standard solutions. Data were ex-
pressed as micrograms of collagen per milligram dry weight, assuming that
collagen contains an average of 13.5% hydroxyproline.
Postmortem Histologic Examination
After echocardiography and hemodynamic examination, 6 rats of each
group were deeply anesthetized and their hearts were exposed through
a median sternotomy. After injection of 10% potassium chloride to arrest
the heart in diastole, the heart was harvested, washed, and immersed in
4% paraformaldehyde for at least 24 hours. The fixed hearts were equidis-
tantly cut into 3 transverse slices. The middle slice was embedded in
paraffin and then sectioned at 5 mm for picrosirius red staining. Histologic
imagines of the stained sections were photographed with Olympus DP70
(Olympus Optical Co, Ltd, Tokyo, Japan) and analyzed with Image-Pro
Plus 6.0 Software (Media Cybernetics, Inc., Bethesda, MD). The follow-
ing parameters were measured: (1) the thickness of scar and septum (av-
erage of 5 equidistant measurements); (2) epicardial and endocardial
circumference, composed by scar and noninfarcted tissue, respectively;
(3) areas composed by collagen and noninfarcted muscle, area of LV cav-
ity, and area of total LV. To evaluate the degree of LV dilation, the expan-
sion index was calculated as LV cavity area/total LV area 3 septum
thickness/scar thickness, as defined by Hochman and Choo.10 All histo-
logic procedure and assay were performed in a blinded fashion.
To demonstrate the ECM microstructure, LV tissue was also stained as
the method described by Rhaleb and colleagues.11 Briefly, the fresh sam-
ples were embedded in optimum cutting temperature (OCT) compound
and cryosectioned at 5 mm. Then the sections were treated with 3.3 U/
mL neuroaminidase type V (Sigma-Aldrich) for 1 hour at room tempera-
ture. After washing in PBS, the sections were stained with 0.10 mg/mL
fluorescein-labeled peanut agglutinin (Vector Laboratories, Burlingame,
Calif). The fields at borderline zone were photographed.
Cardiac Structure and Function Assessment
LVdimension and functionwere assessed by 2-dimensional echocardiogra-
phy in isoflurane-anesthetized animals perioperatively (pre-TA injection and 2
weeks after TA/saline injection. Although echocardiographic examination was
performed for all surviving rats, only 11 rats from each group received echo as-
sessments at the experimental endpoint (4weeks after treatment).Transthoracic
echocardiography was performed using a 12.5-mHz linear-array probe spe-
cially designed for cardiac ultrasonic studies in rat models, with an HP sonos
7500 Imaging System (Philips (China) Investment Co. Ltd., Beijing, China).
LV end-diastolic and end-systolic dimensions (EDD and ESD, respectively)
were measured from the short-axis view of the LV at the midpapillary level.
The LVFSwas calculated as FS¼ (EDDESD)/EDD3 100%. All measure-
ments were performed in triplicate in a blinded fashion. Furthermore, to evalu-
ate the global cardiac contractile function, hemodynamic measurements were
performed for 6 rats of each group at 4 weeks after treatment. A 2-French,
high-fidelity, catheter-tipped micromanometer (model SPR-869, Millar Inc.,
Houston, Tex) was advanced into the ascending aorta and LV through the right
carotid artery to record aorta and LV hemodynamic parameters.218 The Journal of Thoracic and Cardiovascular SurStatistics
All data are presented as mean  standard deviation. SPSS software
package for windows (version 10.0; SPSS, Chicago, Ill) was used for anal-
ysis. One-way analysis of variance test was performed in the cytotoxicity
assessment. Other comparison between groups was made by Student t test.
RESULTS
In vitro Cytotoxicity Assessment
The MTT assay of TA for cardiomyocytes showed that
0.05% TA had minimal cytotoxic effects (Figure 2). No sta-
tistical differences were observed between cells exposed to
0.025% and 0.05% (P ¼ .053) solutions. To maximize
the therapeutic effect of TA while avoiding its cytotoxicity,
we selected 0.05% TA for the use of local injection.
Surgical Mortality
In total, 80 rats were enrolled into the present study and 13
of them died within the first 24 hours after the creation ofMI.
After the first echocardiographic study, another 7 rats were
excluded owing to the unqualified LV function. Therefore,
eventually we got 60 qualified rats for the following studies.
However, 2 rats died after TA injection during the operation
and no more died in the following study time. In the saline
solution injection group, 1 rat died during injection and an-
other died 2 days after injection. All rats that died were ex-
cluded from the study.
MMP Enzymatic Activities, but not Expression, Was
Inhibited by TA
The inhibition of MMP activity by TA was confirmed by
gelatin zymography assay. Twenty-four hours after treat-
ment, in the lanes loaded with samples from the control
group, 1 major transparent band corresponding to MMP-9
and 2 transparent bands corresponding to proMMP-2 and
MMP-2 were observed. One week after treatment (day 8
after MI), the gelatinolytic activity of MMP-2/-9 declined,
and only weak lytic bands were found in control group.
FIGURE 2. In vitro tannic acid (TA) cytotoxicity test. Cardiomyocytes
were exposed to increasing concentrations of TA for 30 minutes, and then
the viability was assessed byMTT assay (n¼ 5 per group). Statistically sig-
nificant differences (*P<0.05 and **P<0.001) were relative to the neg-
ative control group. PBS, Phosphate-buffered saline solution.gery c January 2009
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were observed at either of these 2 times (Figure 3,
A and C). These results indicate that the collagenases
(MMP-2/-9) were highly activated 48 hours after MI and
this activation was dramatically inhibited by TA injection
and that this in vivo inhibitory effect probably could last at
least 1 week. When 50 mg/mL TA was added to the incuba-
tion buffer, the gelatinolytic activity of MMP-2/-9 in sam-
ples from control group was also significantly inhibited
(Figure 3, B), which suggests that the existence of TA can
directly inhibit the enzymatic activities of MMP-2/-9.
However, there was no difference in proMMP-2, MMP-
2/-9, and TIMP-2 expression between TA-treated rats and
saline solution–treated rats 24 hours after treatment, as indi-
cated by Western blotting assay (Figure 3, D).
Early Collagen Content Increased in TA-Treated
Heart
The effect of TA treatment on collagen network stabiliza-
tion was evaluated by biochemical quantification assay. One
week after treatment, the collagen content in infarcted area
was significantly higher in the TA group than the controlThe Journal of Thoracic and Cgroup (48.6  7.2 vs 37.3  6.0 mg/mg dry weight, P ¼
0.027). But up to 4 weeks after treatment, the collagen con-
tent progressively increased, and the difference between the
two groups vanished (72.5  10.6 vs 69.4  9.1 mg/mg dry
weight, P ¼ 0.64).
Evaluation of Cardiac Function
Based on echocardiography examination at the short-axis
view of the midpapillary level, both diastolic and systolic di-
mensions of the LV, as well as the calculated LV FS, were
improved in the TA treatment group at each time point
(Figure E1). On the other hand, in a hemodynamic analysis
at 4 weeks after treatment, no significant difference was
noted in systolic and diastolic blood pressure, as well as
the maximal rising and dropping rate of LV pressure over
time (dP/dt) (Table E1).
Cardiac Morphometry Evaluation
As shown in Figure 4, B and D, ECM was shown to have
a more parallel and well-arranged structure in TA group than
the control with the fluorescent staining. TA treatment sig-
nificantly increased the scar thickness as compared withC
S
PFIGURE 3. Matrix metalloproteinase (MMP)-2/-9 activity was inhibited by tannic acid (TA) treatment. TA1 to TA4 and C1 to C4were samples from the TA
group and the control group, respectively. A, Twenty-four hours after injection, gelatin zymography assay showed that MMP activity was significantly in-
hibited by TA treatment. B, After adding TA into the incubation buffer with a final concentration of 50 mg/mL, the gelatinolytic activity of C1 to C4 (same
samples as in Figure 2, A) was also inhibited in another gel. C, One week after injection, the MMP-2/-9 activity had declined, but the inhibitory effect of TA
still remained. D, Western blotting assay for samples 24 hours after TA/saline injection, which indicated that there was no significant difference in the
expression level of MMP-2, MMP-9, and their inhibitor TIMP-2.ardiovascular Surgery c Volume 137, Number 1 219
Cardiopulmonary Support and Physiology Zhang et al
C
S
PFIGURE 4. Histologic examinations of tannic acid– (TA) and saline solution–treated rats. A and C, Two representative slices stained with picrosirius red
from control and TA group, respectively. Fluorescein-labeled peanut agglutinin staining demonstrated the microstructure of extracellular matrix (ECM) at the
borderline zone. B, Sample from saline solution–injected rat, indicating that the ECMwas arranged in a mess, and some were probably newborn. In contrast,
sample D was from TA-treated rat, and the ECM fibers were mostly aligned parallel to each other and much more in order. ECM was stained green and the
unstained black area represented the survival myocytes.the saline solution injection group (Figure 4, A and C). The
scar length, expressed as the percentage of the total LV cir-
cumference composed of collagen, was also significantly
smaller in TA treatment group than in control (Table E1).
And the infarct area, also expressed as the percentage of
the total LV area, was smaller in TA group. As a global
marker for LV post-MI remodeling, the expansion index
was also reduced after TA treatment.
DISCUSSION
In the acute phase post-MI, tissue ischemia and necrosis
occur, followed by activation of MMP and enzymatic deg-
radation of the ECM network, which causes thinning and
expansion of the infarcted myocardium. Early infarct expan-
sion has been identified as the inciting event that initiates
adverse remodeling. Once established, ventricular dilation
is difficult to reverse and prognosticates a poor long-term
outcome. Although it is well known that the enzymatic deg-
radation and collapse of ECM play an important role in
post-MI ventricular remodeling, only few therapeutic strat-
egies have been attempted to preserve or restore the ECM
after MI.
In the present study, we chose TA injection as a novel
internal cardiac support approach at 24 hours after MI to
attenuate LV remodeling. The major findings of this study
included: (1) TA with an appropriate concentration had220 The Journal of Thoracic and Cardiovascular Sura very low cytotoxicity for the cardiomyocytes; (2) intra-
myocardial injection of TA can increase early collagen
content and inhibit MMP activity in the infarcted area early
after MI; and (3) TA treatment significantly increased scar
thickness, limited scar expansion, and attenuated LV dila-
tion but did not improve the heart intrinsic contractile
ability.
TA is a natural plant-derived chemical and has many ben-
eficial actions on humans, such as anti-inflammation and an-
tithrombosis.12 In cardiovascular research, TA has been
widely used for the fixation of bioprosthetic materials such
as pericardium, heart valve, and vascular scaffold. Here,
for the first time, we examined direct intramyocardial injec-
tion of TA in the treatment of MI. Compared with previous
biomaterials fixation studies, the concentration of TA in the
present study was dramatically reduced (from 0.3% for reg-
ular fixation purpose to 0.05% for the present study). At this
concentration, TA has very low cyototoxicity on the cultured
cardiomyocytes.
Based on the above in vitro cytotoxicity study, we tested
the efficacy of TA injection at the acute stage post-MI. In our
study, TA treatment was shown to be effective in preserving
the collagen network from enzymatic degradation and con-
sequently attenuated the scar expansion and adverse remod-
eling. This was verified by early collagen content assay at 1
week after injection. In previous studies, it was suggestedgery c January 2009
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Pthat TA can cross-link collagen and elastin fibers by intro-
ducing hydrogen bonds, and thus stabilize the ECM in bio-
prosthetic materials fixation.2 TA was thought to be able to
complex or cross-link proteins by the formation of multiple
hydrogen bonds and contribute to the stabilization and pres-
ervation of the dermal matrix. Isenburg and associates2 also
introduced the cross-linking properties of TA into the treat-
ment of aortic aneurysms. They reported that acute localized
periadventitial delivery of noncytotoxic concentrations of
pentagalloyl glucose (one derivative of TA) can inhibit elas-
tin degeneration, attenuate aneurysmal diameter expansion,
and hinder development of abdominal aortic aneurysm. In
the early stage of MI, the infarcted areas remain vulnerable
to expansion or even rupture until enough new ECM scaf-
fold has been produced and matured sufficiently to resist
the distending forces. The cross-linkage can protect the ex-
isting ECM from enzymatic degradation and accelerate the
establishment of new collagen and elastin.
However, up to 3 weeks later, we did not observe a signif-
icant difference of collagen content. This result may be
explained by the fact that in the first week after MI, the
degradation of ECM outpaces its synthesis. While in the fol-
lowing healing stage, synthesis process is more prominent
and new collagen is deposited. This alteration of degrada-
tion-synthesis balance may thus conceal the antidegradation
effects of TA treatment at 4 weeks after MI. Moreover, TA is
hydrosoluble and may be eluted out after a certain period, so
one single-dose injection might not maintain a sustained and
long-term effect on the ECM. Thus, other delivery methods,
such as repeated transendocardial injection and pericardial
perfusion, should be considered.
Another rationale supporting the present study is that TA
may suppress MMP activity. MMPs are major contributors
to the enzymatic degradation of ECM during LV remodel-
ing. In previous tumor study, it has been demonstrated that
green tea polyphenol caused strong inhibition of MMP-2,
-9, and -12.4 Furthermore, it also was suggested that gallate
residue was the most important component of the polyphe-
nol and related to its inhibitory effect. TA contains abundant
gallate residue and thus can interact with MMP. We found
TA treatment significantly inhibited MMP-2/-9 activity 24
hours after TA injection (Figure 3, A), and this inhibitory ef-
fect was maintained for at least 1 week (Figure 3, C). Be-
cause of the probable astringent and anti-inflammation
effects of TA, it was thought that TA treatment may inhibit
inflammation and consequently inhibit the expression of
MMP. Thus we also evaluated the protein level of MMP-
2/-9 and their inherent inhibitor TIMP-2 in the infarcted
myocardium. However, no significant difference was found
between the rats with or without TA treatment (Figure 3, D).
Although we failed to find evidence that TA could influence
the expression of MMP, we confirmed that TA can directly
inhibit the total proteolytic activity of MMP in another gel-
atin zymography assay. When we supplemented TA in theThe Journal of Thoracic and Cincubation buffer (the final concentration was 50 mg/mL,
one tenth of the concentration of the TA used for in vivo in-
jection), the gelatinolytic activity of proMMP-2, MMP-2,
and MMP-9 in samples from control group was also in-
hibited (Figure 3, B). Therefore, we concluded that after
TA local injection, the direct enzyme inhibition effect, to-
gether with collagen cross-linking, may synergistically con-
tribute to preserve and stabilize the ECM structure.
Echocardiography and postmortem morphometry tests
suggested that TA treatment was beneficial in retarding
LV dilation and functional deterioration (Figure E1). But un-
fortunately, it seemed that TA treatment did not improve
systolic and diastolic blood pressure and positive and nega-
tive dP/dt, as showed in hemodynamics examination (Table
E1). Compared with stem cell therapy and therapeutic angio-
genesis, TA treatment did not increase the myocardial perfu-
sion and supply fresh new myogenic cells to restore the
myocardium. Hence, it would be comprehensible that TA
treatment cannot improve the heart intrinsic contractile abil-
ity, although it can maintain the integrity of ECM and atten-
uate the adverse remodeling. Our results are consistent with
those reported by researchers who injected exogenous colla-
gen directly into MI area. Dai and associates13 found that
collagen injection did not affect the LV contractile ability,
although it thickened the scar and improved the LV stroke
volume and ejection fraction. Therefore, if the TA treatment
is translated into clinical practice, it is expected to be consid-
ered as a supplemental therapy to maintain the integrity of
ECM, and additional revascularization procedures should
be performed concomitantly to improve the contractile abil-
ity of cardiomyocytes.
We also tested the body weight, liver enzyme, and creati-
nine level (data not shown), and we did not find any abnor-
mality in TA group as compared with the controls. Local
0.05% TA intramyocardial injection should result in no
obvious systemic toxicity. Therefore, the current study
presents a safe and novel therapeutic strategy for themanage-
ment of acuteMI.MMP activation and ECMdegradation can
occurwithinminutes after ischemia and peak 1 to 2 days after
MI. Fang and associates14 reported that LV rupture mostly
occurred at a narrow time window of 2 to 6 days after MI,
when the original ECM of infarct was degraded and while
the healing process was not efficient. Hence, we directly in-
jected TA at 1 day after the creation of MI. However, further
experiments are needed to determine the optimal time for TA
injection. Last, a paradigm shift in the understanding of ma-
trix biology is that the ECM not only provides the structural
support for cells but also provides a dynamic microenviron-
ment for cell signaling within the intercellular space.15 The
fixation of the interstitial collagen would increase the stiff-
ness and influence the physiologic turnover and the signaling
functions of ECM. On the other hand, the effect of increased
scar on the injured LV in the long term may negatively im-
pact diastolic properties of the ventricle and may be anardiovascular Surgery c Volume 137, Number 1 221
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Parrhythmogenic substrate. Therefore, the long-term studies
in large-animal models will be required before this interven-
tion is given clinical consideration.
In summary, we intramyocardially injected TA at the
early postinfarction stage, and this preclinical study, for
the first time, elucidated a new internal cardiac support ap-
proach. We found that TA injection can increase the early
collagen content of infarct, thicken the scar, limit scar expan-
sion, and attenuate LV remodeling but did not improve the
intrinsic contractile ability. This study offered a promising
approach to preserve the ECM architecture after MI.
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Zhang et al Cardiopulmonary Support and PhysiologyFIGURE E1. Evaluation of left ventricular dimension and function by
echocardiography. There was no significant difference in the EDD, ESD,
and FS between the 2 groups at the baseline. At 2 and 4 weeks after treat-
ment, all 3 parameters in the TA group improved significantly compared
with the control group (*P<0.05, **P<0.001). LVEDD, Left ventricular
end-diastolic dimension; LVESD, left ventricular end-systolic dimension;
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PTABLE E1. Parameters of left ventricular structure and function 4 weeks after treatment
TA group Saline solution group P value
Hemodynamics
Systolic blood pressure (mm Hg) 93.8  8.2 90.6  8.5 .56
Diastolic blood pressure (mm Hg) 70.6  6.9 73.1  8.2 .61
þdP/dt (mm Hg/s) 3,879  213 3,855  173 .85
dP/dt (mm Hg/s) 1,407  316 1,543  156 .41
Postmortem morphometry
Scar thickness (mm) 764  63 485  36 <.001
Infarcted area (%) 16.0  2.3 20.3  2.7 <.001
LV circumference of scar (%) 46.6  7.5 65.7  8.9 .026
Infarct expansion index 1.04  0.15 1.42  0.21 .010
þdP/dt, Rate of left ventricular pressure rise;dP/dt, rate of left ventricular pressure drop; TA, tannic acid; LV, left ventricular.222.e2 The Journal of Thoracic and Cardiovascular Surgery c January 2009
